NCT05263882 2022-03-03Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast CancerFifth Affiliated Hospital, Sun Yat-Sen UniversityPhase 2 Unknown58 enrolled